



## Editas Medicine to Participate in Upcoming Investor Conferences

September 4, 2020

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences:

### **Citi's 15<sup>th</sup> Annual BioPharma Virtual Conference**

Panel: Innovation in Cell Therapy

Date: Wednesday, September 9, 2020

Time: 3:20 p.m. ET

### **Wells Fargo 2020 Virtual Healthcare Conference**

Fireside Chat

Date: Thursday, September 10, 2020

Time: 10:40 a.m. ET

### **Morgan Stanley 18<sup>th</sup> Annual Global Healthcare Conference**

Fireside Chat

Date: Tuesday, September 15, 2020

Time: 10:15 a.m. ET

The events will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the events.

### **About Editas Medicine**

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit [www.editasmedicine.com](http://www.editasmedicine.com).

### **Investor Contact**

Mark Mullikin

(617) 401-9083

[mark.mullikin@editasmed.com](mailto:mark.mullikin@editasmed.com)

### **Media Contact**

Cristi Barnett

(617) 401-0113

[cristi.barnett@editasmed.com](mailto:cristi.barnett@editasmed.com)



Source: Editas Medicine, Inc.